全文获取类型
收费全文 | 2548篇 |
免费 | 150篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 117篇 |
妇产科学 | 121篇 |
基础医学 | 234篇 |
口腔科学 | 70篇 |
临床医学 | 293篇 |
内科学 | 454篇 |
皮肤病学 | 115篇 |
神经病学 | 134篇 |
特种医学 | 184篇 |
外科学 | 228篇 |
综合类 | 159篇 |
预防医学 | 190篇 |
眼科学 | 90篇 |
药学 | 169篇 |
1篇 | |
中国医学 | 76篇 |
肿瘤学 | 59篇 |
出版年
2021年 | 29篇 |
2020年 | 24篇 |
2018年 | 32篇 |
2017年 | 28篇 |
2016年 | 31篇 |
2015年 | 41篇 |
2014年 | 58篇 |
2013年 | 62篇 |
2012年 | 85篇 |
2011年 | 85篇 |
2010年 | 71篇 |
2009年 | 70篇 |
2008年 | 78篇 |
2007年 | 89篇 |
2006年 | 74篇 |
2005年 | 55篇 |
2004年 | 56篇 |
2003年 | 56篇 |
2002年 | 59篇 |
2001年 | 45篇 |
2000年 | 34篇 |
1999年 | 48篇 |
1998年 | 51篇 |
1997年 | 59篇 |
1996年 | 51篇 |
1995年 | 51篇 |
1994年 | 61篇 |
1993年 | 38篇 |
1992年 | 29篇 |
1991年 | 34篇 |
1990年 | 37篇 |
1989年 | 42篇 |
1988年 | 41篇 |
1987年 | 66篇 |
1986年 | 53篇 |
1985年 | 47篇 |
1984年 | 51篇 |
1983年 | 36篇 |
1982年 | 33篇 |
1981年 | 39篇 |
1980年 | 25篇 |
1979年 | 17篇 |
1967年 | 19篇 |
1959年 | 36篇 |
1958年 | 59篇 |
1957年 | 88篇 |
1956年 | 46篇 |
1955年 | 75篇 |
1954年 | 67篇 |
1953年 | 17篇 |
排序方式: 共有2711条查询结果,搜索用时 15 毫秒
81.
Hematopoietic defects in mice lacking the sialomucin CD34 总被引:9,自引:5,他引:9
Cheng J; Baumhueter S; Cacalano G; Carver-Moore K; Thibodeaux H; Thomas R; Broxmeyer HE; Cooper S; Hague N; Moore M; Lasky LA 《Blood》1996,87(2):479-490
Although the pluripotent hematopoietic stem cell can only be definitively identified by its ability to reconstitute the various mature blood lineages, a diversity of cell surface antigens have also been specifically recognized on this subset of hematopoietic progenitors. One such stem cell-associated antigen is the sialomucin CD34, a highly O-glycosylated cell surface glycoprotein that has also been shown to be expressed on all vascular endothelial cells throughout murine embryogenesis as well as in the adult. The functional significance of CD34 expression on hematopoietic progenitor cells and developing blood vessels is unknown. To analyze the involvement of CD34 in hematopoiesis, we have produced both embryonic stem (ES) cells and mice that are null for the expression of this mucin. Analysis of yolk saclike hematopoietic development in embryoid bodies derived from CD34- null ES cells showed a significant delay in both erythroid and myeloid differentiation that could be reversed by transfection of the mutant ES cells with CD34 constructs expressing either a complete or truncated cytoplasmic domain. Measurements of colony-forming activity of hematopoietic progenitor cells derived from yolk sacs or fetal livers isolated from CD34-null embryos also showed a decreased number of these precursor cells. In spite of these diminished embryonic hematopoietic progenitor numbers, the CD34-null mice developed normally, and the hematopoietic profile of adult blood appeared typical. However, the colony-forming activity of hematopoietic progenitors derived from both bone marrow and spleen is significantly reduced in adult CD34-deficient animals, and these CD34-deficient progenitors also appear to be unable to expand in liquid cultures in response to hematopoietic growth factors. Even with these apparent progenitor cell deficiencies, CD34- null animals showed kinetics of erythroid, myeloid, and platelet recovery after sublethal irradiation that are indistinguishable from wild-type mice. These data strongly suggest that CD34 plays an important role in the formation of progenitor cells during both embryonic and adult hematopoiesis. However, the hematopoietic sites of adult CD34-deficient mice may still have a significant reservoir of progenitor cells that allows for normal recovery after nonmyeloablative peripheral cell depletion. 相似文献
82.
Yvonne Linger Alexander Kukhtin Julia Golova Alexander Perov Amine Lambarqui Lexi Bryant George B. Rudy Kim Dionne Stefanie L. Fisher Nicole Parrish Darrell P. Chandler 《Journal of clinical microbiology》2014,52(6):2100-2107
We developed a simplified microarray test for detecting and identifying mutations in rpoB, katG, inhA, embB, and rpsL and compared the analytical performance of the test to that of phenotypic drug susceptibility testing (DST). The analytical sensitivity was estimated to be at least 110 genome copies per amplification reaction. The microarray test correctly detected 95.2% of mutations for which there was a sequence-specific probe on the microarray and 100% of 96 wild-type sequences. In a blinded analysis of 153 clinical isolates, microarray sensitivity for first-line drugs relative to phenotypic DST (true resistance) was 100% for rifampin (RIF) (14/14), 90.0% for isoniazid (INH) (36/40), 70% for ethambutol (EMB) (7/10), and 89.1% (57/64) combined. Microarray specificity (true susceptibility) for first-line agents was 95.0% for RIF (132/139), 98.2% for INH (111/113), and 98.6% for EMB (141/143). Overall microarray specificity for RIF, INH, and EMB combined was 97.2% (384/395). The overall positive and negative predictive values for RIF, INH, and EMB combined were 84.9% and 98.3%, respectively. For the second-line drug streptomycin (STR), overall concordance between the agar proportion method and microarray analysis was 89.5% (137/153). Sensitivity was 34.8% (8/23) because of limited microarray coverage for STR-conferring mutations, and specificity was 99.2% (129/130). All false-susceptible discrepant results were a consequence of DNA mutations that are not represented by a specific microarray probe. There were zero invalid results from 220 total tests. The simplified microarray system is suitable for detecting resistance-conferring mutations in clinical M. tuberculosis isolates and can now be used for prospective trials or integrated into an all-in-one, closed-amplicon consumable. 相似文献
83.
Holger W. Auner Sarah R. Brown Katrina Walker Jessica Kendall Bryony Dawkins David Meads Gareth J. Morgan Martin F. Kaiser Mark Cook Sadie Roberts Christopher Parrish Gordon Cook 《Blood cancer journal》2022,12(4)
The all-oral combination of ixazomib, cyclophosphamide, and dexamethasone (ICD) is well tolerated and effective in newly diagnosed and relapsed multiple myeloma (MM). We carried out MUKeight, a randomised, controlled, open, parallel group, multi-centre phase II trial in patients with relapsed MM after prior treatment with thalidomide, lenalidomide, and a proteasome inhibitor (ISRCTN58227268), with the primary objective to test whether ICD has improved clinical activity compared to cyclophosphamide and dexamethasone (CD) in terms of progression-free survival (PFS). Between January 2016 and December 2018, 112 participants were randomised between ICD (n = 58) and CD (n = 54) in 33 UK centres. Patients had a median age of 70 years and had received a median of four prior lines of therapy. 74% were classed as frail. Median PFS in the ICD arm was 5.6 months, compared to 6.7 months with CD (hazard ratio (HR) = 1.21, 80% CI 0.9–1.6, p = 0.3634). Response rates and overall survival were not significantly different between ICD and CD. Dose modifications or omissions, and serious adverse events (SAEs), occurred more often in the ICD arm. In summary, the addition of ixazomib to cyclophosphamide and dexamethasone did not improve outcomes in the comparatively frail patients enroled in the MUKeight trial.Subject terms: Drug development, Cancer therapy, Cancer therapy 相似文献
84.
Recombinant human granulocyte colony-stimulating factor (G-CSF) treatment has been shown to increase average neutrophil counts substantially in patients with childhood-onset cyclic neutropenia (or "cyclic hematopoiesis"), but not to eliminate the cyclic oscillations of neutrophil counts or those of other blood elements (monocytes, platelets, eosinophils, and reticulocytes) that are characteristic of this hematopoietic disorder. Indeed, oscillations of neutrophil counts are amplified during G-CSF treatment. We have compared the effects of recombinant granulocyte-macrophage-CSF (GM-CSF) with those of G-CSF in three patients with this disease (2 men and 1 woman, 17, 30, and 32 years of age). These patients were treated with GM-CSF (2.1 micrograms/kg/day, subcutaneously) for 6 weeks, preceded and followed by 6 to 13 weeks of detailed observation to document changes in the cyclic oscillations of blood neutrophils and other blood elements; two of the patients were subsequently treated with G-CSF (5.0 micrograms/kg/d, subcutaneously) and observed for comparable periods of time. Unlike G-CSF treatment, which increased average neutrophil counts more than 20-fold, GM-CSF increased neutrophil counts only modestly, from 1.6- to 3.9-fold, although eosinophilia of varying prominence was induced in each patient. However, at the same time, GM-CSF treatment dampened or eliminated the multilineage oscillations of circulating blood elements (neutrophils, monocytes, platelets, and/or reticulocytes) in each of the patients. In contrast, G-CSF treatment of the same patients markedly amplified the oscillations of neutrophil counts and caused the cycling of other blood elements (monocytes in particular) to become more distinct. These findings support the conclusion that the distinctive cycling of blood cell production in childhood-onset cyclic neutropenia results from abnormalities in the coordinate regulation of both GM-CSF-responsive, multipotential progenitor cells and G-CSF-responsive, lineage-restricted, neutrophil progenitors. 相似文献
85.
二氧化碳气腹对肿瘤细胞生长和播散影响的研究 总被引:4,自引:0,他引:4
目的 研究静脉使用 5 %NaHCO3 纠正CO2 气腹造成的酸中毒能否改善其对肿瘤细胞的促生长和播散作用。方法 观察静脉推注 5 %NaHCO3 的CO2 气腹组、CO2 气腹组及对照组带瘤Wister大鼠的肿瘤生长及穿刺点转移情况。结果 静脉推注 5 %NaHCO3 的CO2 气腹组、CO2 气腹组及对照组肿瘤的重量、体积和腹水体积有差异 ,但无统计学意义。穿刺点转移率无明显差异。结论 CO2 气腹影响肿瘤细胞生长和播散的机制复杂 ,不能完全以CO2 引起机体酸中毒解释。未找到通过静脉推注 5 %NaHCO3 可改善CO2 气腹对肿瘤细胞生长影响的基础理论依据。 相似文献
86.
87.
88.
89.
90.